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Abstract
Neointimal hyperplasia, stimulated by injury and certain vascular diseases, promotes artery
obstruction and tissue ischemia. In vascular smooth muscle cell (VSMCs), multiple modula-
tors of protein handling machinery regulate intimal hyperplasia. These include elements of
the VSMC unfolded protein response to endoplasmic reticulum stress (UPRER), and trans-
glutaminase 2 (TG2), which catalyzes post-translational protein modification. Previous
results for deficiency of UPRER-specific mediator XBP1, and of TG2, have been significant,
but in multiple instances contradictory, for effects on cultured VSMC function, and, using
multiple models, for neointimal hyperplasia in vivo. Here, we engineered VSMC-specific
deficiency of XBP1, and studied cultured VSMCs, and neointimal hyperplasia in response to
carotid artery ligation in vivo. Intimal area almost doubled in Xbp1fl/fl SM22α-CRE+ mice 21
days post-ligation. Cultured murine Xbp1 deficient VSMCs migrated more in response to
platelet derived growth factor (PDGF) than control VSMCs, and had an increased level of
inositol-requiring enzyme 1α (Ire1α), a PDGF receptor-binding UPRER transmembrane
endonuclease whose substrates include XBP1. Cultured XBP1-deficient VSMCs demon-
strated decreased levels of TG2 protein, in association with increased TG2 polyubiquitina-
tion, but with increased TG transamidation catalytic activity. Moreover, IRE1α, and TG2-
specific transamidation cross-links were increased in carotid artery neointima in Xbp1fl/fl
SM22α-CRE+ mice. Cultured TG2-deficient VSMCs had decreased XBP1 associated with
increased IRE1α, and increased migration in response to PDGF. Neointimal hyperplasia
also was significantly increased in Tgm2fl/fl SM22α-CRE+ mice at 21 days after carotid liga-
tion. In conclusion, a VSMC regulatory circuit between XBP1 and TG2 limits neointimal
hyperplasia in response to carotid ligation.
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Introduction
Neointimal hyperplasia, characterized by cellular and extracellular matrix expansion, is an
arterial phenotype that can be triggered by direct endothelial injury, indirect and disease-asso-
ciated vessel injury, and disruption of blood flow [1–8]. Specific conditions that can trigger
neointimal hyperplasia include shear stress, mechanical (post-revascularization) and hyperten-
sive injury to endothelium, and diseases such as atherosclerosis and inflammatory vasculitis
(eg, giant cell arteritis) [1–8]. Significantly, neointimal hyperplasia in response to arterial
injury, such as angioplasty, can be rapid and produce marked arterial stenosis or restenosis
[9].
Cells involved in neointimal hyperplasia can be activated by agonists including PDGF,
angiotensin II, and certain inflammatory cytokines and danger signals [1,4,5,8]. Responses to
such mediators, including VSMC synthetic to proliferative differentiation phenotype switch,
migration into the intima from the artery media, and apoptosis, play a core role in determining
outcome in multiple models of neointimal hyperplasia [1–8]. Important VSMC responses to
stress include proteostasis pathways, as well as intersection of elements of the protein handling
machinery [1–4,8]. For example, UPRER is a physiologic response to cell stress due to accumu-
lation of unfolded or misfolded proteins in the ER [10–14]. UPRER processes include signaling
cascades initiated through 3 distinct ER-resident transmembrane proteins [10–15]. Down-
stream effects include limitation of protein translation, and induction of expression of multiple
chaperones. These responses facilitate successful resolution of cell stress, via augmented capac-
ities for protein folding, and degradation of unfolded and misfolded proteins [10–15]. Signifi-
cantly, excess induction of C/EBP homologous protein (CHOP) in UPRER promotes
neointimal hyperplasia post-injury and atherosclerosis progression, via increased oxidative
stress and apoptosis [16,17]. IFNγ, through stimulation of ubiquitin-dependent liver X recep-
tor- degradation, exacerbates neointimal hyperplasia as a result of induction of ER stress and
apoptosis in macrophages [8].
Several processes pertinent to intimal hyperplasia are promoted by activation of the trans-
membrane endonuclease inositol requiring enzyme-1α (IRE1α) pathway of the UPRER
[10,14,15]. These include activation of inflammatory signaling via transmembrane IRE1α-
induced phosphorylation of IκB kinase (IKK) and c-Jun N-terminal kinase (JNK) [10,14,15],
and direct interaction between IRE1 and PDGFRβ that promotes downstream responses to
PDGF [1]. IRE1 plays a mediating role in cultured VSMC proliferation in response to PDGF,
as shown by IRE1 siRNA knockdown [1,2]. Injured arterial intima demonstrate the UPRER-
specific process of alternative splicing and activation of mRNA of the transcription factor
XBP1 by generating the transcriptionally active form of XBP1, termed XBP1s [1]. This process
is executed via upstream endonuclease activity of IRE1 [10,14,15]. However, results of 2 prior
studies have been contradictory for effects on cultured VSMCs and neointimal hyperplasia of
XBP1 [1,2].
The ubiquitously expressed enzyme TG2 has been implicated in intimal hyperplasia [3,4].
TG2 not only cross-links proteins by transamidation, but also modulates the autophagy arm of
the proteostasis network, and functions as a protein disulfide isomerase and as a GTPase and
GTP-modulated signal transducer [18,19]. Effects of TG2 to promote arterial diseases include
mediation of PDGF and β-catenin signaling in VSMCs, and promotion of VSMC prolifera-
tion, migration, and phenotypic switching [3,4,20]. Conversely, the capacity of TG2 to inhibit
certain cytokines and MMPs, and to interact with fibronectin and transforming growth factor-
β, can promotes stabilization of the arterial extracellular matrix [21]. Global knockout of TG2
markedly limited inhibited neointimal hyperplasia in response to carotid artery loop injury
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(3), but either inhibited or failed to inhibit neointimal hyperplasia in response to carotid artery
ligation in two different studies [3,4].
Since both XBP1 and TG2 regulate a variety of cell homeostasis and injury response pro-
cesses, this study investigated the relationship between XBP1 and TG2 in VSMCs. To simplify
our approach to study VSMC responses, we focused on effects of VSMC-specific deficiency of
XBP1 and TG2 in neointimal hyperplasia in response to carotid artery ligation, a model that
does not involve endothelial denudation [22]. In doing so, we assessed for cross-talk between
XBP1 and TG2 in VSMCs. Our results reveal a VSMC regulatory circuit between XBP1 and
TG2 that limits neointimal hyperplasia in response to carotid artery ligation.
Materials and methods
Materials
Tunicamycin was from Sigma-Aldrich (St. Louis, MO). Enhanced chemiluminescence
reagents, 5-(biotinamido)pentylaminewere, horseradish peroxidase (HRP)-conjugated strepta-
vidin, and BCA protein assay reagents were from Thermo Fisher (Carlsbad, CA). DMEM and
penicillin/streptomycin were from Thomas Scientific (Swedesboro, NJ), fetal bovine serum
was Gemini Bio Products (West Sacramento, CA), and HRP-conjugated goat anti-mouse IgG
was from Thermo Fisher. Protein G- HRP conjugated was from Bio-Rad (Hercules, CA).
SYBR Green for qPCR assay was obtained from Roche (Indianapolis, IN). Nε-(γ-L-glutamyl)-
L-lysine-isopeptide antibody was obtained from Zedira GmbH (Germany) XBP1 siRNA and
TG2 siRNA were from Santa Cruz Biotechnologies (Dallas, TX) (sc-38628). All other reagents
were from Sigma-Aldrich.
Plasmids employed
6x His-SUMO-1 {1–97} (Accession number P62165), 6x His-SUMO-2 {1–92} (Accession
number CAG46970) or 6x His-SUMO-3 {1–93} (Accession number CAA67897) were kindly
provided by Dr. Michael Tatham (University of Dundee, UK). HA-TG2 (human) was cloned
into pcDNA3.1 (+) (Life Technologies, Inc.) (EcoR1 and Not1 sites) using the primers (for-
ward 5’-AAACCCGAATTCCTATCCTTACGACGTGCCTGACTACGACATGGCC GAGGAG
CTGGTCTTAGAGAG-3’; reverse 5’-AAACCCGCGGCCGCTTAGGCGGG CCAATGATG
ACATTCCG-3’). Xbp1s (mouse) (XBP-1 2: pFLAG.XBP1p.CMV2, plasmid #21833) was
from Addgene.org (Cambridge, MA). Control plasmid pFLAG-CMV2 (Cat. # E7033) was
from Sigma-Aldrich. Murine Tgm2 cDNA (Accession BC016492, clone 3256943) purchased
from Dharmacon (Lafayette, CO; Cat# MMM1013-202702036).
Generation of mice lacking XBP1 or TG2 in SMCs (Xbp1Δ and Tgm2Δ
mice)
All animal experiments were reviewed and approved by the San Diego VA Medical Center ani-
mal subjects committee. Xbp1fl/fl mice with loxP sites flanking exon 2 of Xbp1, a gift of Dr.
Laurie Glimcher (Harvard Medical School, Boston, MA) [23], were backcrossed with SM22α-
cre mice (B6.Cg-Tg(Tagln-cre)1Her/J; Jackson laboratories, cat.# 017491, Bar Harbor, ME)
that express α-actin-dependent Cre recombinase activity specific to SMCs [24]. The mice were
backcrossed for more than 10 generations onto the C57BL/6 background, were born at a Men-
delian ratio and developed normally. To generate mice lacking Tgm2 (Tgm2Δ) in SMCs,
Tgm2flox/flox mice, possessing loxP sites flanking exons 6–8 of Tgm2 [25] were cross-bred with
SM22α-Cre transgenic mice.
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Carotid artery ligation
Eight weeks old mice were anesthetized by intraperitoneal injection of a solution of xylazine (5
mg/kg body weight, AnaSed; Lloyd Laboratories), ketamine (80 mg/kg body weight) and ace-
promazine maleate (1.2 mg/kg (Boehringer Ingelheim, St. Joseph, MO). We followed a proto-
col previously described in detail [7]. In brief, the left common carotid artery was ligated near
its bifurcation with the use of 6–0 silk, with right carotid artery as uninjured control. At 14 and
21 days after injury, animals were anesthetized and perfused with 5 ml PBS, followed by 5 ml
of 4% paraformaldehyde for 3 min. Left and right carotid arteries were excised, further fixed
for 16 hours and embedded transversely in paraffin. The entire length of and lesion apex iden-
tified. For morphometric analyses, images of Verhoeff-van Gieson elastin-stained cross-sec-
tions of left and right carotid arteries (6 micron thickness) were analyzed in a blinded manner
using AxionVision microscope (Carl Zeiss, AG Oberkochen, DE), and intimal and medial area
calculated [7].
For immunohistochemistry (IHC) analyses, paraffin-embedded ligated carotid artery sec-
tions were deparaffinized, followed by digestion with 0.125% Trypsin for antigen retrieval.
BSA-blocked slides were incubated with primary antibody overnight at 4˚C. We used rabbit
anti-Nε-(γ-L-glutamyl)-lysine-isopeptide bond, and anti–total IRE1α (NB100-2324; Novus
Biologicals, Littleton, CO) antibodies. Horseradish peroxidase (HRP)-conjugated secondary
antibody was from Thermo Fisher (Cat# 878963). Diaminobenzidine was the substrate for col-
orimetric detection.
VSMC isolation and culture
To isolate primary mouse VSMCs, aortae from 8 weeks old mice were isolated (from aortic
root to bifurcation of the renal arteries) and media was digested, as described (7). VSMC dif-
ferentiation was verified by staining for smooth muscle -actin (mouse monoclonal antibody;
cat#ab7817, Abcam) by immunofluorescence (>95% of cells stained positive for smooth mus-
cle -actin). VSMCs were cultured in complete DMEM medium at 37˚C, in 5% CO2. Mouse
VSMC line Movas-1 cells (ATCC CRL-2797, Manassas, VA), were transfected with XBP1
siRNA (Santa Cruz Biotechnology, sc-38628) where indicated, and collected at 24 h and 48 h
post transfection and lysed in RIPA buffer and cell proteins immunoprecipitated using Dyna-
beads (Thermo Fisher).
In Situ Tissue Transglutaminase (tTG) activity assay of TG2
For in situ TG2 activity measurements, XBP1Δ SMCs were preincubated with 5-(biotinamido)
pentylamine (Thermo Fisher), a biotinylated polyamine TG2 substrate that the enzyme can
use to post-translationally modify proteins, followed by determination of its incorporation
into proteins.[26] We measured absorbance at 492 nm on microplate spectrophotometer. As a
negative control, we used Tgm2Δ VSMCs treated under identical conditions, and Xbp1WT
VSMCs served as the positive controls for normal levels of TG2 activity.
Transwell migration assay
To determine cell proliferation, we used the Invitrogen non-radioactive Cell Proliferation
Assay kit, per manufacturer instructions. VSMC migration was assayed, as previously
described [7]. In brief, we used a Transwell plate (Cat #3422, 8 μm pore size, Corning, Sunny-
vale, CA), with VSMCs plated at 1.0 x 106 cells/ml in DMEM supplemented with 10% heat-
inactivated fetal calf serum [7]. Numbers of cells migrated per well, were determined after 48 h
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treatment with or without PDGF, as described [7]. Images were analyzed using a microscope
with digital camera (EVOS).
SDS-PAGE/Western blot analyses
Primary VSMCs were homogenized and lysed in RIPA buffer supplemented with protease
inhibitor tablets (Roche). Protein was separated (10 μg, for each sample) on gradient (4–12%)
SDS-PAGE, followed by semi-dry transfer onto PVDF membranes (Millipore, Bedford, MA).
Membranes were immunoblotted with primary antibody and the appropriate horseradish per-
oxidase-conjugated secondary antibody (Bio-Rad). Immunoblots were analyzed by enhanced
chemiluminescence technique (Thermo Fisher). Primary antibodies to IRE1α, TG2, GAPDH,
SUMO1, SUMO2/3, HA, and K48 ubiquitin were from Cell Signaling Technology (Beverly,
MA).
Quantitative reverse transcription (RT)-PCR
RNA was extracted and isolated from cultured smooth muscle cells, utilizing RNeasy mini kit
(Qiagen, Hilden, DE). RNA levels were quantified using a Nanodrop 1000 spectrophotometer
(Thermo Fisher); samples with 260 nm/280 nm absorbance ratios >2.0 were used for RT.
Equal amounts of total RNA from each sample underwent RT reaction, using Transcriptor
High Fidelity cDNA Synthesis Kit (Roche), which includes anchored oligo(dT)18 and random
hexamer primers. Quantitative RT-PCR was done using a Roche480 Light Cycler and mouse-
specific primer sets: XBP1s: XBP1s-F: GAGTCCGCAGCAGGTG; XBP1s-R: GTGTCA
GAGTCCATGGGA; XBP1-F: CACCTTCTTGCCTGCTGGAC; XBP1-R: GGGAGCCCTCA
TATCCACAGT [27]; and TGM2-F: AATGCTCCTATTGGCCTGTACCGT, TGM2-R:
AGCCTTGGTAGATGAAGCCCTGTT; GAPDH-F: GGAGCGAGACCCCACTAACA, GAP
DH-R: CCTGCTTCACCACCTTCTTGA. Expression of genes of interest was calculated as
fold change from control.
Morphometry
Morphometric analysis was carried out on carotid arteries harvested at 14 and 21 days after
ligation. All animals were perfused and fixed under physiological pressure. Images of arteries
were analyzed with Axion Vision Software (Carl Zeiss AG, Oberkochen, DE). Additionally,
under the assumption that the structures were circular, measurements were used to calculate
intimal and medial area.
SUMOylation assay
To analyze SUMOylation within cells, we used Lipofectamine 2000 to transfect HeLa cells
(ATCC CRL-2, Manassas, VA) with plasmids encoding wild-type HA-TGM2 along with either
SUMO1, SUMO2 and SUMO3 plasmids respectively. Cells were selected and grown according
to a previously described protocol [28]. Cell lysates were immunoprecipitated with a HA-spe-
cific affinity matrix gel (Roche, Pleasanton, CA), after which immunoprecipitate was washed
in lysis buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 1 mM DTT, 10%
glycerol, 10 mM EDTA), followed by elution and proteins resolved by SDS-PAGE and immu-
noblotted using TG2 antibody, RanGAP antibody (Cell Signal, cat# 36067), and protein G
HRP-conjugate (BioRad, Hercules, CA).
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Fig 1. Increased neointimal hyperplasia after carotid artery ligation in Xbp1 VSMC-specific knockout mice. (A) Mice were studied 14 to 21 days
after carotid artery ligation. Verhoff-van Gieson elastin staining of representative sections of Xbp1fl/fl (Xbp1WT) and Xbp1lf/fl;SM22α-Cre (Xbp1Δ)
XBP1 and TG2 cross-talk in neointimal hyperplasia
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Statistical analyses
All values are expressed as mean ± SD. Statistical differences between WT and mutant mice or
cells were analyzed by a Student’s t-test. Morphometric analysis of carotid artery was done by
1-way ANOVA. Differences were considered statistically significant at values of p<0.05. Data
for cell culture experiments represent three experiments in triplicates using separate cultures.
Results
Increased intimal thickening after carotid artery ligation in mice with
VSMC-specific XBP1 deficiency
We generated Xbp1Δ mice (Xbp1 fl/flSM22α-Cre), in which Xbp1 exon 2 was efficiently deleted
specifically in aortic VSMCs. In parallel, we similarly generated Tgm2Δ mice (Tgm2fl/flSM22α-
Cre). Unlike the case for isolated VSMCs, in the Xbp1Δ and Tgm2Δ mouse whole tissues stud-
ied, there was no gross attenuation of XBP1 or TG2, respectively (S1 Fig).
Neointimal hyperplasia developed in carotid arteries, in response to ligation, in both
Xbp1WT and Xbp1Δ mice. This phenotypic response was significantly increased in Xbp1Δ
mice (Fig 1A). The lumen of the ligated carotid arteries was larger in Xbp1WT mice than in
Xbp1Δ mice (Fig 1A, whereas intima-media ratio was significantly increased in Xbp1Δ mice
compared to Xbp1WT animals (Fig 1B)). In isolated, cultured aortic VSMCs from Xbp1Δ mice
treated with PDGF, there was significantly increased migration but not proliferation, com-
pared to control cells (Fig 1C).
XBP1 modulates TG2 and IRE1α in VSMCs
Isolated VSMCs from cultured XBP1 deficient mouse aortae demonstrated decreased TG2
(Fig 2A). Conversely, TG2-deficient VSMCs demonstrated decrease in XBP1u (Fig 2A). Trans-
fection of XBP1s into XBP1-deficient VSMCs significantly increased TG2 protein (Fig 2C and
inset). Silencing of either XBP1 or TGM2 expression by siRNA in MOVAS-1 cells affected the
protein expression level of the other protein (Fig 2D). Paradoxically, XBP1 deficiency in vitro
was associated with increased activity of the TG2 present, as assessed by tTG assay [29](Fig
2E). In response to carotid ligation, the carotid artery sections, analyzed by IHC using an anti-
body to Nε-(γ-L-glutamyl)-lysine-isopeptide bond, showed increase of the selective TG2
crosslinking marker in Xbp1Δ carotid arteries compared to wild type (Fig 2F).
IRE1α has multiple binding partners, and many effects on cell differentiation and function
independent of action on XBP1 [10,14,15,30,31]. Hence, we assessed IRE1α levels in vitro and
in situ. In VSMCs extracted from aortae of the conditional knockout mice, we observed
increased IRE1α levels in Xbp1Δ, and also, though to a lesser degree, more IRE1α in Tgm2Δ
cells (Fig 3B). Similarly, IRE1α was increased in MOVAS-1 cells in which Xbp1 was knocked
down by siRNA (Fig 3C). Moreover, we observed markedly increased IRE1α immune staining
in neointima in situ in carotid artery sections of XBP1Δ mice (Fig 3D). The mRNA levels for
Tgm2 and Xbp1 did not significantly decrease with deficiency of the other protein in cultured
VSMCs (S2 Fig). Thus, we next tested for effects of XBP1 deficiency on the stability of TG2.
demonstrated substantial plaque development after 14 and 21 days post ligation. (B) Intima-media ratio was compared for Xbp1WT vs Xbp1Δ at 14
days post ligation (p<0.0001 n = 8 Xbp1WT; n = 12 Xbp1Δ), and at 21 days, where intimal cell densities were increased in both Xbp1WT and Xbp1Δ
(p<0.0001, unpaired t-test, n = 10 Xbp1WT; n = 11 Xbp1Δ;). (C) Xbp1Δ (Xbp1f/f;SM22α-Cre) and Xbp1WT (Xbp1f/f) aortic VSMCs were treated
with PDGF (10 ng/ml) for 18h. The numbers of cells migrated, and proliferated, were studied as described in the Methods. XBP1 deficiency
increased VSMC migration (assessed as the increase in migration in response to PDGF relative to no PDGF) in vitro (p<0.0001; n = 4). XBP1
deficiency did not significantly increase proliferation in response to PDGF. Data represent mean ± SD of 4 independent experiments. Results were
analyzed by 1-way ANOVA, followed by Bonferroni correction).
https://doi.org/10.1371/journal.pone.0212235.g001
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XBP1 affects TG2 stability in VSMCs
TG2 levels significantly increased in Xbp1Δ VSMCs treated over time with the proteasome
inhibitor MG132 (Fig 4A). Since XBP1 deficiency appeared to promote increased proteasomal
TG2 degradation, we next studied TG2 SUMOylation. We also assessed if TG2 cellular stability
was potentially subject to dynamics between TG2 SUMOylation and ubiquitylation [32]. To
do so, we generated stable HeLa cell lines expressing distinct SUMO molecules (SUMO1,
SUMO2 and SUMO3) [33,34], and we transfected these cells with TG2-HA expression plas-
mid. We first confirmed [32] that TG2 was SUMOylated by SUMO1, (Fig 4B), and predomi-
nantly modified by SUMO2 and to lesser extent by SUMO3. The SUMOylation was compared
to control RanGAP SUMOylation (S3 Fig). To test whether TG2 ubiquitylation/SUMOylation
dynamics can be affected by XBP1 deficiency, MOVAS-1 cells were transfected with XBP1
siRNA, followed by immunoprecipitation at different post transfection times. TG2 demon-
strated reduced SUMOylation (SUMO1) in response to Xbp1 knockdown, and, conversely,
there was increased TG2 K48-linked ubiquitylation (Fig 4C), which is known to promote pro-
teasomal degradation [35].
Increased intimal thickening after carotid artery ligation in TGM2Δ mice
Neointimal hyperplasia and associated lumen occlusion developed in the ligated carotid arter-
ies of both Tgm2WT and Tgm2Δ mice, and these responses were significantly increased in
Tgm2Δ mice (Fig 5A and 5B). Last, isolated Tgm2Δ aortic VSMCs demonstrated both
increased migration and proliferation in response to PDGF compared to Tgm2WT (Fig 5C).
Discussion
VSMC responses to stress are modulated by the UPR, other proteostasis pathways, and by the
multifunctional molecule TG2, a component of the protein handling machinery [1–4,8]. This
study identified a regulatory circuit in VSMCs via cross-talk between TG2 and XBP1, a tran-
scription factor whose activation by IRE1 endonuclease action is a UPR-specific event [11–14].
Specifically, deficiency of XBP1 or TG2 promoted decrease in the level of the other respective
protein in VSMCs. These changes were not associated with corresponding alteration of XBP1
or TGM2 mRNA levels due to deficiency of TG2 or XBP1, respectively. Instead, we demon-
strated an increased capacity of XBP1-deficient cells to promote TG2 proteasomal degradation
by increase in K48 polyubiquitylation relative to SUMOylation. Protein SUMOylation has the
capacity to promote protein stabilization, in part by blocking ubiquitination at lysine residues,
and partly because SUMOylated proteins have a distinct overall surface charge distribution
compared to ubiquitin [33,34]. XBP1 was previously recognized to regulate ER-associated pro-
tein degradation and to have major effects on the transcriptional profile of the proteostasis net-
work, and on successful UPR resolution [12,13]. These new findings on regulation of TG2 by
Fig 2. Modulation of endogenous TG2 protein levels by XBP1 in VSMCs. (A) Cell lysates of primary aortic VSMCs from Xbp1Δ (Xbp1fl/fl; SM22α-
Cre) and Xbp1WT (Xbp1 fl/fl) mice were analyzed by SDS-PAGE-Western blot to determine endogenous levels of TG2, XBP1, Cre recombinase, and
GAPDH. TG2 protein levels were significantly higher in WT vs XBP1Δ SMCs with p<0.001 (n = 4 separate experiments), as determined by
densitometry. (B) Cell lysates from primary aortic VSMCs of Tgm2Δ (Tgm2 fl/fl; SM22α-Cre) and Tgm2WT (Tgm2 fl/fl) were analyzed by Western
blotting to determine levels of TG2, XBP1, Cre recombinase and GAPDH. Absence of TG2 was noted in the Tgm2Δ cells. (C) Representative Western
blot of lysates of Xbp1Δ VSMCs transfected with Xbp1s or control plasmid (Unpaired t-test p =<0.0001; n = 4 separate experiments) showed
increased TG2 protein with Xbp1 transfection. (D) MOVAS-1 cell XBP1 siRNA or TGM2 siRNA knockdown induced decrease in both TG2 and
XBP1 protein levels (One-way ANOVA) (E) In situ TG2 (tTG) activity in Xbp1 WT and Xbp1Δ VSMCs, determined by incorporation of 5-
(biotinamido)pentylamine into protein, showed increased TG2 activity in the Xbp1Δ cells. Data were analyzed using Student’s t-test. (F) Carotid
artery sections for Tgm2Δ, Tgm2 WT, Xbp1Δ and Xbp1WT were probed with antibody against Nε-(γ-L-glutamyl)-lysine-isopeptide bond.
Representative results of IHC from studies of 3 separate animals of each genotype showed enhanced TG2-mediated crosslinking activity in Xbp1Δ
sections compared to Xbp1WT.
https://doi.org/10.1371/journal.pone.0212235.g002
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XBP1 suggest additional means by which XBP1 can modulate cell fate and inflammatory
responses following activation of the IRE1 arm of the UPR [10–12,36–38].
VSMCs, as well as endothelial, vascular precursor, and inflammatory cells, and platelets have
been implicated in neointimal hyperplasia [1–8]. Arterial wire injury, employed in several of
these studies, is designed to resemble post-revascularization injury in stenotic human arteries
[22]. However, endothelial injury, and substantial roles of inflammatory cell influx and activation
in such murine models of neointimal hyperplasia, render arterial wire injury mechanistically
and cellularly more complex than carotid artery ligation [22]. The carotid ligation model is trig-
gered by marked reduction of vessel diameter and attenuation of blood flow, with consequent
effects on arterial wall shear stress stimulating rapid VSMC-enriched neointima formation [22].
Our study focused squarely on VSMC biology via unique use of newly generated SMC-specific
knockout mice for Xbp1 and Tgm2, and we examined only neointimal hyperplasia following
carotid artery ligation.
We demonstrated that both SMC-specific XBP1 and TG2 deficiency increased neointimal
hyperplasia in response to carotid artery ligation in vivo. In complementary in vitro studies
here, VSMCs isolated from aortae of both these conditional knockout animals were observed
to migrate more in response to PDGF. Furthermore, TG2-deficient VSMCs proliferated more
in response to PDGF than did VSMCs from control animals. Here, as in prior studies involv-
ing XBP1 and TG2 [1–4], results for cultured VSMC responses to PDGF, and for neointimal
hyperplasia were largely aligned. However, multiple differences existed between the conclu-
sions of prior studies VSMC XBP1 function in vitro and in neointimal hyperplasia in vivo
[1,2], now magnified by results of our study. In one prior report, global Xbp1 haploinsuffi-
ciency increased neointimal hyperplasia in response to femoral artery wire injury, and XBP1
siRNA augmented cultured human coronary VSMC migration and proliferation in response
to PDGF [2]. In contrast, SM22α-targeted SMC-specific Xbp1 deficiency increased neointimal
hyperplasia in response to femoral artery wire injury in another prior report [1]. Overexpres-
sion XBP1s increased human VSMC migration, and conversely, cell migration out of aortic
ring explants was decreased by Xbp1 knockout in one study [2]. However, XBP1 deficiency in
cultured VSMCs failed to significantly alter PDGF-induced migration in the same report [2].
Differences in results from small animal neointimal hyperplasia models partly reflect dis-
tinctions in experimental model behavior between species, but also expose differences between
pathogeneses of models [22]. It is possible that factors in discrepancies between findings on
XBP1 in VSMC behavior and neointimal hyperplasia include differences in degree of experi-
mental depression of XBP1 levels, and impact of distinct protocols and reagents and agonists,
such as using VEGF or PDGF as agonist. Also involved may be beneficial effects downstream
of XBP1 in stressed cells, such as modulation of apoptosis and autophagy [11–13], successful
resolution of proteotoxic cell stress, and prevention of oxidative stress by modulating reactive
oxygen species generation and catalase expression [39]. Conversely, XBP1s promotes activa-
tion of VSMCs via PI3K/Akt signaling and the capacity to down-regulate calponin h1 through
mir-1274B-mediated mRNA degradation [1]. Increases in VSMC PDGF and PDGF receptor
levels in XBP1-deficient VSMCs [2], and in IRE1α levels as observed here, also merit
Fig 3. XBP1 and TG2 deficiency promote increased IRE1α protein levels in cultured VSMCs and in neointima in situ. (A) Cell lysate protein
(10 μg aliquots) from cultured primary Xbp1WT and Xbp1Δ aortic VSMCs, and Tgm2 WT and Tgm2Δ VSMCs (B) were analyzed for IRE1α, with
XBP1, TG2, and GAPDH as internal controls, using SDS-PAGE/Western blotting (Densitometry analyzed by Ordinary one-way ANOVA; n = 4) (C)
MOVAS-1 cells transfected with either XBP1 siRNA or TG2 siRNA were probed for IRE1α. The Figure shows representative results (n = 4 separate
experiments, p<0.0001, Ordinary one-way ANOVA) for SDS-PAGE/Western blotting of cell lysates using antibodies against IRE1α, with TG2, XBP1,
and GAPDH as internal controls. (D) Xbp1WT and Xbp1Δ WT and (E) Tgm2 WT and Tgm2Δ carotid artery sections were analyzed by IHC for total
IRE1α.
https://doi.org/10.1371/journal.pone.0212235.g003
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consideration. IRE1α endonuclease activity is critical to induce XBP1 activation by generating
alternatively spliced XBP1s transcript [12,13], but IRE1α also can enhance downstream effects
of PDGF receptor signaling [10,14,15]. Moreover, IRE1α endonuclease and kinase activities
have multiple additional consequences on cell differentiation and function independent of
action on XBP1 [10,14,15]. These include activation of inflammatory signaling and cytokine
expression via transmembrane IRE1α -induced phosphorylation of IKK and JNK [12–15], and
direct interaction between IRE1 and PDGFRβ that promotes downstream responses to PDGF
[1].
TG2 not only has been observed to increase VSMC migration and proliferation in vitro
[3,4], but also to promote inward remodeling of injured arteries in vivo [40]. Moreover, previ-
ous work observed significant decreases, in global TG2 knockout mice, of neointima forma-
tion in both PDGF-treated heart slices and in carotid arteries following ligation [3,4].
Significantly, prior study reported attenuated neointimal hyperplasia following carotid artery
loop injury in global TG2 knockout mice, though there no significant difference between
global TG2 knockout and wild type mice in neointimal hyperplasia following carotid artery
ligation [3]. As such, our finding that SMC-specific TG2 deficiency increased neointimal
hyperplasia, in response to carotid artery ligation, could be viewed as paradoxical. However,
we did observe that XBP1 deficiency was associated with increased VSMC TG activity in vitro,
and neointimal TG2 protein cross-links in response to carotid artery ligation in vivo. Hence,
our results suggest a model in which increased transamidation activity of TG2, and potentially
reciprocal decrease in GTPase-related TG2 activity, as well as decrease in TG2 levels and non-
enzymatic activities, could be among the mechanisms whereby stressed XBP1-deficient
VSMCs can promote neointimal hyperplasia.
Limitations of this study include that it did not specifically examine effects of VSMC XBP1
and TG2 deficiencies on the extracellular matrix synthesis and composition, or on cell viabil-
ity, and on the global proteostasis network. Tgm2 deficient VSMCs had a proliferative response
to PDGF-BB (10 ng/ml). However, fleshing out individual factors mediating the migration
response in TG2-deficient VSMCs was beyond the scope of this study. It will be of interest to
test for potential contributory effects of mitochondrial function regulation by the IRE-XBP1
signaling axis [41] in arterial VSMC responses to vascular injury. It remains to be determined
if the VSMC XBP1 and TG2 regulatory loop defined here has generalized impact across inti-
mal hyperplasia disease models, including restenosis after direct endothelial denudation
injury.
We conclude that cross-talk between XBP1 and TG2 in VSMCs is substantially involved in
limiting the extent of neointimal hyperplasia in carotid arteries injured by ligation. Our find-
ings identify how dysregulated UPR and protein handling machinery responses can not only
be intertwined but also amplify adverse adaptive responses to tissue injury. The results provide
further support for the potential of systemically and locally controlling the UPR and TG2 to
productively intervene in the phenotype of tissue responses to injury.
Fig 4. XBP1 deficiency in VSMCs affects TG2 SUMOylation and ubiquitylation. (A) Xbp1Δ VSMCs were treated with the proteasome inhibitor
MG132 over 6 h, and samples collected at 30, 60, 180 and 360 minutes during this time period. At each time point, cell lysate samples were analyzed
by probing Western blots with TG2-specific antibody. (B) HeLa stable lines expressing SUMO proteins, (SUMO1, SUMO2 and SUMO3) and
transfected with human HA-TGM2 construct, were immunoprecipitated using HA-TAG magnetic beads. The eluates were probed using anti-HA
antibody. (C) MOVAS-1 cells were transfected with Xbp1 siRNA, followed by harvesting at 24 h and 48 h thereafter. Homogenates (100 μg aliquots)
were immunoprecipitated using TG2-specific antibody and eluates analyzed by Western blots using antibodies to TG2, K48-ubiquitin, and SUMO1.
(D) The effect of Xbp1 siRNA knockdown on the level of TG2 in MOVAS-1 cells is shown in the Figure (Densitometric Analysis, n = 3, Ordinary
one-way ANOVA).
https://doi.org/10.1371/journal.pone.0212235.g004
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Fig 5. Increased intimal thickening after carotid artery ligation in Tgm2 VSMC-specific knockout mice. (A) Verhoff-van Gieson elastin
staining of representative carotid artery sections from Tgm2WT (Tgm2f/f) and Tgm2Δ (Tgm2f/f;SM22α-Cre) mice demonstrated neointimal
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Supporting information
S1 Checklist. ARRIVEGuidelines%20Checklistillable%29%20copyd.pdf: The ARRIVE
Guidelines checklist is attached.
(PDF)
S1 Fig. Levels of XBP1 and TG2 were not attenuated in selected whole tissues from respec-
tive conditional knockout mice. (A) Aliquots of 10 μg of homogenized whole tissues,
extracted from Xbp1 WT and Xbp1Δ animals, and (B) Tgm2 WT and Tgm2Δ animals, were
analyzed by SDS-PAGE/Western blotting to assess levels of XBP1 and TG2 protein, respec-
tively.
(TIF)
S2 Fig. The mRNA levels for Tgm2 and Xbp1 were not suppressed by deficiency of the
other respective molecule. For quantification by qPCR of Tgm2 and Xbp1 in murine VSMCs,
we reverse-transcribed 500 ng of total RNA extracted from cultured smooth muscle cells
(VSMCs). We used qPCR to determine mRNA levels of Tgm2 and Xbp1 in Tgm2WT, Tgm2Δ,
Xbp1WT and Xbp1Δ.
(TIF)
S3 Fig. SUMOylated proteins in homogenates prepared from stable HeLa cell lines
expressing SUMO proteins. For affinity purification of SUMO proteins, we subjected eluates
from Nickel-NTA beads to SDS/PAGE-Western blotting, using TG2 and RanGAP as controls
for protein SUMOylation. The figure shows anti-TG2, RanGAP1 and input immunoblots of
nickel affinity purifications from HeLa cells. The high molecular weight species were detected
by TG2 antibody, with strong signal above ~75kD representing TG2 eluted from Ni-NTA col-
umns. Endogenous TG2 was covalently conjugated to 6His-SUMO1, 2 and 3, with eluates
compared from stable lines expressing SUMO1,2, and 3. RanGAP antibody was able to detect
endogenous protein which is modified by SUMO1, and to lesser extent by SUMO3, and was
used as control for the procedure. Non-specific bands are indicated by asterisks.
(TIF)
S1 Dataset. Sminimaldataset.xlsx: The minimal data set, for the manuscript results pre-
sented here, is attached.
(XLSX)
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